These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

290 related items for PubMed ID: 31112954

  • 21. Desidustat in Anemia due to Non-Dialysis-Dependent Chronic Kidney Disease: A Phase 3 Study (DREAM-ND).
    Agrawal D, Varade D, Shah H, Nazar A, Krishnan J, Shukla V, Ramakrishna C, Bandara Galahitiyawa MC, Mavani SB, Rajanna S, Jikki P, De Silva S, Ruhela V, Koradia P, Kansagra K, Kanani P, Sharma N, Zala K, Parmar D, Study Investigator Group.
    Am J Nephrol; 2022; 53(5):352-360. PubMed ID: 35462372
    [Abstract] [Full Text] [Related]

  • 22. Roxadustat Treatment of Chronic Kidney Disease-Associated Anemia in Japanese Patients Not on Dialysis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial.
    Akizawa T, Iwasaki M, Otsuka T, Reusch M, Misumi T.
    Adv Ther; 2019 Jun; 36(6):1438-1454. PubMed ID: 30953333
    [Abstract] [Full Text] [Related]

  • 23. Four-Week Studies of Oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor GSK1278863 for Treatment of Anemia.
    Holdstock L, Meadowcroft AM, Maier R, Johnson BM, Jones D, Rastogi A, Zeig S, Lepore JJ, Cobitz AR.
    J Am Soc Nephrol; 2016 Apr; 27(4):1234-44. PubMed ID: 26494831
    [Abstract] [Full Text] [Related]

  • 24. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease.
    Pergola PE, Spinowitz BS, Hartman CS, Maroni BJ, Haase VH.
    Kidney Int; 2016 Nov; 90(5):1115-1122. PubMed ID: 27650732
    [Abstract] [Full Text] [Related]

  • 25. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHI) for the treatment of anemia associated with chronic kidney disease.
    Del Vecchio L, Locatelli F.
    Expert Opin Investig Drugs; 2018 Jul; 27(7):613-621. PubMed ID: 29975110
    [Abstract] [Full Text] [Related]

  • 26. Long-Term Efficacy and Safety of Molidustat for Anemia in Chronic Kidney Disease: DIALOGUE Extension Studies.
    Akizawa T, Macdougall IC, Berns JS, Bernhardt T, Staedtler G, Taguchi M, Iekushi K, Krueger T.
    Am J Nephrol; 2019 Jul; 49(4):271-280. PubMed ID: 30852574
    [Abstract] [Full Text] [Related]

  • 27. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials.
    Provenzano R, Szczech L, Leong R, Saikali KG, Zhong M, Lee TT, Little DJ, Houser MT, Frison L, Houghton J, Neff TB.
    Clin J Am Soc Nephrol; 2021 Aug; 16(8):1190-1200. PubMed ID: 34362786
    [Abstract] [Full Text] [Related]

  • 28. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients.
    Wang B, Yin Q, Han YC, Wu M, Li ZL, Tu Y, Zhou LT, Wei Q, Liu H, Tang RN, Cao JY, Lv LL, Liu BC.
    Ren Fail; 2020 Nov; 42(1):912-925. PubMed ID: 32869703
    [Abstract] [Full Text] [Related]

  • 29. First-in-man-proof of concept study with molidustat: a novel selective oral HIF-prolyl hydroxylase inhibitor for the treatment of renal anaemia.
    Böttcher M, Lentini S, Arens ER, Kaiser A, van der Mey D, Thuss U, Kubitza D, Wensing G.
    Br J Clin Pharmacol; 2018 Jul; 84(7):1557-1565. PubMed ID: 29575006
    [Abstract] [Full Text] [Related]

  • 30. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies.
    Nangaku M, Ueta K, Nishimura K, Sasaki K, Hashimoto T.
    Clin Exp Nephrol; 2024 May; 28(5):391-403. PubMed ID: 38530490
    [Abstract] [Full Text] [Related]

  • 31. Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.
    Ha JT, Hiremath S, Jun M, Green SC, Wheeler DC, Coyne DW, Perkovic V, Badve SV.
    NEJM Evid; 2024 Sep; 3(9):EVIDoa2300189. PubMed ID: 39186635
    [Abstract] [Full Text] [Related]

  • 32. Hypoxia-inducible factor-prolyl hydroxylase inhibitors for renal anemia in chronic kidney disease: Advantages and disadvantages.
    Mima A.
    Eur J Pharmacol; 2021 Dec 05; 912():174583. PubMed ID: 34678238
    [Abstract] [Full Text] [Related]

  • 33. The Comparison between Vadadustat and Daprodustat Regarding Dose, Cost, and Safety of Treatment for Renal Anemia in Non-dialysis Patients with Chronic Kidney Diseases.
    Imai E, Imai A.
    Intern Med; 2024 Jul 01; 63(13):1855-1861. PubMed ID: 37926547
    [Abstract] [Full Text] [Related]

  • 34. Future perspectives of anemia management in chronic kidney disease using hypoxia-inducible factor-prolyl hydroxylase inhibitors.
    Sugahara M, Tanaka T, Nangaku M.
    Pharmacol Ther; 2022 Nov 01; 239():108272. PubMed ID: 36031160
    [Abstract] [Full Text] [Related]

  • 35. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents.
    Haase VH, Chertow GM, Block GA, Pergola PE, deGoma EM, Khawaja Z, Sharma A, Maroni BJ, McCullough PA.
    Nephrol Dial Transplant; 2019 Jan 01; 34(1):90-99. PubMed ID: 29672740
    [Abstract] [Full Text] [Related]

  • 36. Novel Compound Induces Erythropoietin Secretion through Liver Effects in Chronic Kidney Disease Patients and Healthy Volunteers.
    Shinfuku A, Shimazaki T, Fujiwara M, Sato F, Watase H, Numazaki T, Kawakita Y, Mutoh M, Yamasaki H, Takayama N, Kato S, Sugimoto T, Maruyama J.
    Am J Nephrol; 2018 Jan 01; 48(3):157-164. PubMed ID: 30176654
    [Abstract] [Full Text] [Related]

  • 37. Cardiovascular safety and efficacy of vadadustat for the treatment of anemia in non-dialysis-dependent CKD: Design and baseline characteristics.
    Chertow GM, Pergola PE, Agarwal R, Block GA, Farag YMK, Jardine AG, Koury MJ, Luo W, Khawaja Z, Lewis EF, Matsushita K, McCullough PA, Parfrey PS, Wittes J, Walters KA, Tseng C, Lin T, Sarnak MJ, Vargo DL, Winkelmayer WC, Eckardt KU.
    Am Heart J; 2021 May 01; 235():1-11. PubMed ID: 33129989
    [Abstract] [Full Text] [Related]

  • 38. HIF stabilizers in the management of renal anemia: from bench to bedside to pediatrics.
    Kular D, Macdougall IC.
    Pediatr Nephrol; 2019 Mar 01; 34(3):365-378. PubMed ID: 29569190
    [Abstract] [Full Text] [Related]

  • 39. [Renal anemia and hypoxia-inducible factor prolyl hydroxylase inhibitor].
    Maruno S, Tanaka T, Nangaku M.
    Rinsho Ketsueki; 2021 Mar 01; 62(5):371-377. PubMed ID: 34108317
    [Abstract] [Full Text] [Related]

  • 40. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study.
    Provenzano R, Bhaduri S, Singh AK, PROMPT Study Group.
    Clin Nephrol; 2005 Aug 01; 64(2):113-23. PubMed ID: 16114787
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.